Health Tech Capitol | Cellectar Earns Allowance for Patent
16159
post-template-default,single,single-post,postid-16159,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Cellectar Earns Allowance for Patent

07 Feb Cellectar Earns Allowance for Patent

Posted at 13:17h in Uncategorized by
0 Likes

The U.S. Patent and Trademark Office awarded Cellectar Biosciences a notice of allowance for a patent covering the use of CLR 131 in multiple myeloma (MM), the company announced today.

“This patent allowance enhances our intellectual property estate and underscores the novelty of CLR 131 for the treatment of multiple myeloma, a life-threatening disease with high unmet medical need,” Cellectar Biosciences CEO James Caruso said in a statement. “Importantly, upon issuance, this patent will extend our coverage into the mid-2030s.”

The U.S. Patent and Trademark Office awards a notice of allowance after an examiner determines that patent application is “in satisfactory condition and meets the requirements.”

Read more at Madison Startups

No Comments

Sorry, the comment form is closed at this time.